tegafur has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 8 studies
Dihydropyrimidine Dehydrogenase Deficiency: An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The main advantage of targeted genotyping is the existence of prospectively validated genotype-based dosing guidelines." | 1.72 | Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). ( Bm Claes, K; Borbath, I; Casneuf, V; Demey, W; Geboes, KP; Haufroid, V; Van den Eynde, M; Verheezen, Y; Verstraete, AG, 2022) |
| " We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www." | 1.39 | Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. ( Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF, 2013) |
| "We strongly suspected a DPD deficiency from the result of urinary pyrimidine analysis." | 1.35 | [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration]. ( Doi, Y; Endo, Y; Ishizuka, S; Kai, K; Matsumoto, Y; Morikawa, T; Nabeyama, A; Nagahiro, W; Nakashima, A; Nobuhisa, T; Sato, S; Watanabe, T; Yamada, T; Yoshida, K, 2008) |
| "We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Casneuf, V | 1 |
| Borbath, I | 1 |
| Van den Eynde, M | 1 |
| Verheezen, Y | 1 |
| Demey, W | 1 |
| Verstraete, AG | 1 |
| Bm Claes, K | 1 |
| Haufroid, V | 1 |
| Geboes, KP | 1 |
| Milano, G | 1 |
| Caudle, KE | 1 |
| Thorn, CF | 1 |
| Klein, TE | 1 |
| Swen, JJ | 1 |
| McLeod, HL | 1 |
| Diasio, RB | 1 |
| Schwab, M | 1 |
| Aragane, H | 1 |
| Suchi, K | 1 |
| Shimomura, M | 1 |
| Katano, T | 1 |
| Yasui, H | 1 |
| Kan, K | 1 |
| Deenen, MJ | 2 |
| Terpstra, WE | 2 |
| Cats, A | 2 |
| Boot, H | 1 |
| Schellens, JH | 2 |
| Mandigers, CM | 1 |
| Soesan, M | 1 |
| Beijnen, JH | 1 |
| Hashimoto, T | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Saze, Z | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Yasutome, M | 1 |
| Hiruma, K | 1 |
| Yamashita, Y | 1 |
| Kai, K | 1 |
| Endo, Y | 1 |
| Yoshida, K | 1 |
| Morikawa, T | 1 |
| Nobuhisa, T | 1 |
| Watanabe, T | 1 |
| Matsumoto, Y | 1 |
| Yamada, T | 1 |
| Doi, Y | 1 |
| Nakashima, A | 2 |
| Nagahiro, W | 1 |
| Ishizuka, S | 1 |
| Sato, S | 1 |
| Nabeyama, A | 1 |
8 other studies available for tegafur and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Topics: Antimetabolites, Antineoplastic; Belgium; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; | 2022 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2013 |
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chemotherapy, Adjuvant; Dihydropyrimidine Dehydr | 2010 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2010 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency | 2012 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
[A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dihydropyrimidine Dehy | 2008 |